Leerink Comments on Tectonic Therapeutics Inc. (TECX) Post Eli Lilly (LLY) Terminating volenrelaxin CKD
Tweet Send to a Friend
Leerink Partners analyst David Risinger reiterated an Outperform rating and $69.00 price target on Tectonic Therapeutics Inc. (NASDAQ: TECX)The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
